CFO, Alpha Tau Medical
Search every verified Raphi Levy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Raphi Levy, CFO of Alpha Tau Medical, presented at the Lytham Partners Spring 2026 Investor Conference on May 27, 2026. He stated that the company had $80 million in cash at the end of the previous quarter and described a burn rate approaching $25 million per year, adding that the company is "well financed for execution." Levy highlighted several clinical trials, including a pancreatic cancer study (Impact) and a brain cancer study (Regain), and noted that final results from a first-in-human pancreatic cancer trial were being presented at ASCO 2026. He said that in an earlier interim analysis of metastatic pancreatic cancer patients who had failed FOLFIRINOX, median survival had not been reached at 15 months of follow-up, compared to an expected 10–11 months per literature. Levy also discussed updates to a pancreatic cancer study, stating that the FDA expanded it to 40 patients across two cohorts receiving either FOLFIRINOX or gemcitabine with nab-paclitaxel. In a separate trial combining Alpha DaRT with Keytruda, he reported that two of three patients had a complete response and the third had stable disease, describing the 67% complete response rate as "completely unheard of" while noting the data are early. He contrasted this with Keytruda alone, which he said is expected to produce a 19% response rate and a 5% systemic complete response rate. Levy said the company is in discussions with the FDA about launching a larger U.S. study for approval in certain patients.
Raphi Levy, CFO of Alpha Tau, joins the Big Biz Show to discuss Alpha DaRT’s targeted cancer therapy, encouraging clinical results across multiple tumor types, and the company’s upcoming catalysts as it advances toward commercialization.
Exactly one year ago, we covered Alpha Tau Medical (DRTS) and their highly targeted, localized radiation therapy, Alpha DaRT. Today, we are breaking down the massive milestones they've hit over the last 12 months! Japan's Ministry of Health just granted them their very first commercial Shonin marketing approval outside of Israel for the treatment of head and neck cancer. On top of that, Alpha Tau recently signed a blockbuster $196 million strategic collaboration with Tolmar International to bring the DaRT wire to prostate cancer patients in the United States. In this video, we dive deep into t…
Investor presentation featuring Alpha Tau Medical Ltd. (NASDAQ: DRTS) from the Lytham Partners Spring 2026 Investor Conference. As part of the conference, Robert Blum, Managing Partner, Lytham Partners, hosted a virtual investor presentation with Raphi Levy, Chief Executive Officer of Alpha Tau Medical. Alpha Tau Medical is an oncology-focused medical technology company developing alpha-radiation therapies designed to target and destroy solid tumors while minimizing damage to surrounding healthy tissue. The company's proprietary Alpha DaRT technology represents a novel approach to cancer tre…
This Biotech Stock Is Disrupting Cancer Treatment - Meet Raphi Levy, CFO, Alpha Tau $DRTS Guest Raphi Levy, CFO, Alpha Tau Company Alpha Tau Website https://www.alphatau.com Ticker: $DRTS Raphi's Bio Raphi Levy has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel. Mr. Levy has served as a director of MX Management LP since April 2022. Mr. Levy holds a B.S. in E…
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we’re showcasing the innovative companies presenting at the upcoming DealFlow Discovery Conference (January 28-29, at the Borgata in Atlantic City) and the executives behind them. In this episode of Mission Matters, I sit down with Raphi Levy, CFO of Alpha Tau, to talk about a groundbreaking approach to cancer treatment that’s designed to target tumors directly. Raphi explains how Alpha Tau’s Alpha DaRT technology works, why it’s shown powerful results…
Alpha Tau Medical CFO Raphi Levy joined Steve Darling from Proactive to discuss the groundbreaking progress of Alpha Tau ...And joining me now is Raphi Levy. He is the CFO for Alpha Tau Medical. And Raphi, it's good to see you. How are you? I'm all ...
Alpha Tau Medical, Inc. (NASDAQ: DRTS) is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Keynote speaker: Raphi Levy, CFO
Alpha Tau Medical, Inc. (NASDAQ: DRTS) is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Keynote speaker: Raphi Levy, CFO
Alpha Tau Medical, Inc. (NASDAQ: DRTS) is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Keynote speaker: Raphi Levy, CFO
Alpha Tau Medical, Ltd. (NASDAQ: DRTS, DRTSW) is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Keynote speaker: Raphi Levy, CFO
Sign in to search the full transcript archive, filter by topic, and access every quote from Raphi Levy.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans